AAPL   320.53 (-0.41%)
MSFT   182.21 (-0.38%)
FB   227.34 (-1.97%)
AMZN   2,450.29 (-0.84%)
CGC   16.19 (-1.76%)
BABA   211.95 (+2.60%)
MU   45.90 (-0.95%)
AMD   52.54 (-2.05%)
T   30.93 (+0.00%)
ACB   13.97 (-0.92%)
F   5.89 (+0.34%)
GILD   73.85 (-1.59%)
BAC   25.10 (+1.95%)
BA   153.34 (+1.29%)
AAPL   320.53 (-0.41%)
MSFT   182.21 (-0.38%)
FB   227.34 (-1.97%)
AMZN   2,450.29 (-0.84%)
CGC   16.19 (-1.76%)
BABA   211.95 (+2.60%)
MU   45.90 (-0.95%)
AMD   52.54 (-2.05%)
T   30.93 (+0.00%)
ACB   13.97 (-0.92%)
F   5.89 (+0.34%)
GILD   73.85 (-1.59%)
BAC   25.10 (+1.95%)
BA   153.34 (+1.29%)
AAPL   320.53 (-0.41%)
MSFT   182.21 (-0.38%)
FB   227.34 (-1.97%)
AMZN   2,450.29 (-0.84%)
CGC   16.19 (-1.76%)
BABA   211.95 (+2.60%)
MU   45.90 (-0.95%)
AMD   52.54 (-2.05%)
T   30.93 (+0.00%)
ACB   13.97 (-0.92%)
F   5.89 (+0.34%)
GILD   73.85 (-1.59%)
BAC   25.10 (+1.95%)
BA   153.34 (+1.29%)
AAPL   320.53 (-0.41%)
MSFT   182.21 (-0.38%)
FB   227.34 (-1.97%)
AMZN   2,450.29 (-0.84%)
CGC   16.19 (-1.76%)
BABA   211.95 (+2.60%)
MU   45.90 (-0.95%)
AMD   52.54 (-2.05%)
T   30.93 (+0.00%)
ACB   13.97 (-0.92%)
F   5.89 (+0.34%)
GILD   73.85 (-1.59%)
BAC   25.10 (+1.95%)
BA   153.34 (+1.29%)
Log in

NASDAQ:INSMInsmed Stock Price, Forecast & News

$25.70
+0.71 (+2.84 %)
(As of 06/2/2020 11:03 AM ET)
Add
Compare
Today's Range
$24.73
Now: $25.70
$25.93
50-Day Range
$17.38
MA: $22.65
$26.15
52-Week Range
$12.09
Now: $25.70
$34.94
Volume16,777 shs
Average Volume1.31 million shs
Market Capitalization$2.60 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.72
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
Read More
Insmed logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INSM
CUSIPN/A
Phone908-977-9900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$136.47 million
Book Value$2.93 per share

Profitability

Net Income$-254,340,000.00
Net Margins-162.82%

Miscellaneous

Employees373
Market Cap$2.60 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive INSM News and Ratings via Email

Sign-up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.

Insmed (NASDAQ:INSM) Frequently Asked Questions

How has Insmed's stock been impacted by COVID-19 (Coronavirus)?

Insmed's stock was trading at $21.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, INSM stock has increased by 17.6% and is now trading at $25.00. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Insmed?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Insmed.

When is Insmed's next earnings date?

Insmed is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Insmed.

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) issued its earnings results on Thursday, April, 30th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.72) by $0.02. The biopharmaceutical company had revenue of $36.90 million for the quarter, compared to the consensus estimate of $34.81 million. Insmed had a negative return on equity of 87.35% and a negative net margin of 162.82%. The company's revenue for the quarter was up 68.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.96) earnings per share. View Insmed's earnings history.

What price target have analysts set for INSM?

8 analysts have issued 1-year target prices for Insmed's stock. Their forecasts range from $20.00 to $56.00. On average, they expect Insmed's stock price to reach $42.00 in the next twelve months. This suggests a possible upside of 68.0% from the stock's current price. View analysts' price targets for Insmed.

Has Insmed been receiving favorable news coverage?

Media stories about INSM stock have trended very positive on Tuesday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Insmed earned a news impact score of 3.5 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutInsmed.

Are investors shorting Insmed?

Insmed saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 13,480,000 shares, an increase of 12.2% from the April 15th total of 12,010,000 shares. Based on an average daily volume of 1,440,000 shares, the short-interest ratio is presently 9.4 days. Approximately 15.8% of the shares of the stock are sold short. View Insmed's Current Options Chain.

Who are some of Insmed's key competitors?

What other stocks do shareholders of Insmed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include AbbVie (ABBV), Geron (GERN), Johnson & Johnson (JNJ), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Intercept Pharmaceuticals (ICPT), Micron Technology (MU), Opko Health (OPK) and Amarin (AMRN).

Who are Insmed's key executives?

Insmed's management team includes the following people:
  • Mr. William H. Lewis J.D., Pres, CEO & Chairman (Age 50)
  • Mr. Paolo Tombesi, Chief Financial Officer (Age 55)
  • Ms. Christine A. Pellizzari J.D., Chief Legal Officer & Corp. Sec. (Age 51)
  • Mr. Roger Adsett, Chief Commercial Officer (Age 50)
  • Dr. Paul D. Streck, Advisor (Age 55)

What is Insmed's stock symbol?

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Who are Insmed's major shareholders?

Insmed's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (9.83%), Franklin Resources Inc. (2.21%), Eagle Asset Management Inc. (1.67%), Geode Capital Management LLC (1.48%), Carillon Tower Advisers Inc. (1.25%) and Fairmount Funds Management LLC (1.14%). Company insiders that own Insmed stock include Alfred Altomari, Donald J Hayden Jr, John Goll, Melvin Md Sharoky, Orlov S Nicole Schaeffer, Roger Adsett, Steinar J Engelsen and William Lewis. View institutional ownership trends for Insmed.

Which major investors are selling Insmed stock?

INSM stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Russell Investments Group Ltd., Foresite Capital Management IV LLC, Foresite Capital Management II LLC, JPMorgan Chase & Co., Granahan Investment Management Inc. MA, Raymond James & Associates, and Rafferty Asset Management LLC. Company insiders that have sold Insmed company stock in the last year include John Goll, Orlov S Nicole Schaeffer, and William Lewis. View insider buying and selling activity for Insmed.

Which major investors are buying Insmed stock?

INSM stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., William Blair Investment Management LLC, AXA, Cormorant Asset Management LP, Lord Abbett & CO. LLC, Scout Investments Inc., Geode Capital Management LLC, and WCM Investment Management LLC. Company insiders that have bought Insmed stock in the last two years include Melvin Md Sharoky, Roger Adsett, Steinar J Engelsen, and William Lewis. View insider buying and selling activity for Insmed.

How do I buy shares of Insmed?

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Insmed's stock price today?

One share of INSM stock can currently be purchased for approximately $25.00.

How big of a company is Insmed?

Insmed has a market capitalization of $2.53 billion and generates $136.47 million in revenue each year. The biopharmaceutical company earns $-254,340,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. Insmed employs 373 workers across the globe.

What is Insmed's official website?

The official website for Insmed is www.insmed.com.

How can I contact Insmed?

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.